Evidence map›Paper›PMID 25613762›Full record

ReviewDrugs2015

Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients.

Karly P Garnock-Jones

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03828058 (A 12 Month Single-center, Open Label, Randomized, Comparative Study to Evaluate Envarsus XL Steroid-free Rabbit Anti-thymocyte Globulin Induction on Renal Function and Health-related Quality of Life Following Liver Transplantation), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03828058 phase2completednot on this mapstarted 2019, after this paper: background citation

A 12 Month Single-center, Open Label, Randomized, Comparative Study to Evaluate Envarsus XL Steroid-free Rabbit Anti-thymocyte Globulin Induction on Renal Function and Health-related Quality of Life Following Liver Transplantation

TypeinterventionalSponsorMethodist Healthcare - MemphisRan2019 to 2020Enrolled110ConditionsRecipients of Liver TransplantArmsEnvarsus XR, Prograf
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Review
  11. Real-World Administration of Once-Daily MeltDoseJournal of clinical medicine · 2020
    Article
  12. Article
  13. Observational
  14. Article
  15. Epidemiology of carbapenem-resistantAntimicrobial resistance and infection control · 2018
    Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Karly P Garnock-JonesSpringer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand, demail@springer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tacrolimus prolonged release (Envarsus®; henceforth referred to as tacrolimus PR) is a new, once-daily, prolonged-release tacrolimus formulation, utilizing a drug delivery technology designed to enhance the bioavailability of drugs with low water solubility by creating a solid solution of the drug. This article reviews the pharmacological properties of tacrolimus PR and its clinical efficacy and tolerability in adult kidney and liver transplant recipients. In phase III trials, tacrolimus PR was noninferior to tacrolimus immediate release (IR; twice daily) in both de novo and stable, previously treated kidney transplant recipients, and had a similar tolerability profile. Preliminary efficacy data from phase II trials in de novo and stable, previously treated liver transplant recipients imply that tacrolimus PR is effective in these patient groups; however, more data would be of interest. Pharmacokinetic analyses demonstrated that tacrolimus PR is associated with a higher bioavailability, reduced peak-trough concentration fluctuation ratio, lower mean values for percentage degree of fluctuation and percentage degree of swing, and a longer time to maximum concentration than tacrolimus IR. Tacrolimus PR is a promising addition to the treatment options available for kidney and liver transplant recipients.

Indexed as

Kidney TransplantationLiver TransplantationCalcineurin InhibitorsClinical Trials as TopicDelayed-Action PreparationsDrug InteractionsGraft RejectionHumansImmunosuppressive AgentsTacrolimusTreatment OutcomeCalcineurin InhibitorsDelayed-Action PreparationsImmunosuppressive AgentsTacrolimus

Identifiers

PMID25613762

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.